Phase 2 Melanoma Trial, Recruiting NCT07099430 Sponsor: Nanjing Leads Biolabs Co.,Ltd Condition: Melanoma
Back to Melanoma

Phase 2 Melanoma Trial, Recruiting

NCT07099430
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to follow the trial's treatment plan, attend all scheduled visits, complete required tests, and sign a consent form agreeing to take part
  • You are 18 years old or older (any gender)
  • You are generally well enough to carry out light activity and care for yourself, based on a standard fitness scale used in cancer research (confirm with trial site)
  • Your doctor expects you to live for at least 12 weeks
  • You have at least one tumour that can be measured using standard medical scans
  • If you are able to have children (male or female), you are willing to use highly effective birth control from the time you sign the consent form until at least 6 months after your last dose of the trial drug

Who may not be able to join:

  • You received a live vaccine in the 4 weeks before starting the trial, or plan to receive one during the trial or within 4 weeks of finishing it
  • You had major surgery or a significant medical procedure or test within the 4 weeks before starting the trial
  • You have an active autoimmune disease, or have had one in the past that could come back (confirm with trial site)
  • You have a history of serious heart or stroke-related conditions
  • You currently have an active infection
  • You have a history of significant mental illness that could affect your ability to understand or consent, or a history of substance abuse or addiction
  • You are currently pregnant or breastfeeding
  • The trial doctor feels there are other reasons that make participation unsuitable for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yu Chen, Fujian Cancer Hospital

Phone: 025-83378099

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Nanjing Leads Biolabs Co.,Ltd
Registry
ClinicalTrials.gov
Start date
5 September 2025
Est. completion
30 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Occurrence of adverse event (AE) and serious adverse event (SAE); Objective Response Rate (ORR); Progression-free Survival(PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov